Table 3.
Initial antibiotic treatment in elderly patients admitted with pneumonia
| Treatment regimen | NHAP (n = 58) | CAP (n = 151) | p value |
|---|---|---|---|
| Monotherapy | 22 (37.9) | 26 (17.2) | 0.001 |
| 3rd cepha | 1 (1.7) | 1 (0.6) | 0.479 |
| Fluoroquinolone | 6 (10.3) | 18 (11.9) | 0.749 |
| Anti-pseudomonal agenta | 15 (25.8) | 7 (4.6) | < 0.001 |
| Combination therapy | 36 (62.0) | 125 (82.7) | 0.001 |
| 3rd cepha + macrolide | 17 (29.3) | 95 (62.9) | < 0.001 |
| 3rd cepha + fluoroquinolone | 4 (6.8) | 6 (3.9) | 0.469 |
| 3rd cepha + clindamycin | 0 | 3 (1.9) | 0.562 |
| 3rd cepha + macrolide + clindamycin | 3 (5.1) | 8 (5.2) | 1.000 |
| Anti-pseudomonal agent + macrolide | 1 (1.7) | 3 (1.9) | 1.000 |
| Anti-pseudomonal agent + fluoroquinolone | 8 (13.7) | 7 (4.6) | 0.033 |
| Anti-pseudomonal agent + clindamycin | 2 (3.4) | 1 (0.6) | 0.187 |
| Vancomycin + anti-pseudomonal agent | 1 (1.7) | 2 (1.3) | 1.000 |
| Use of anti-pseudomonal agent | 30 (51.7) | 20 (13.2) | < 0.001 |
| Use of anti-MRSA agent | 1 (1.7) | 2 (1.3) | 1.000 |
Values are presented as number (%).
NHAP, nursing home-acquired pneumonia; CAP, community-acquired pneumonia; 3rd cepha, third-generation cephalosporin; MRSA, methicillin-resistant Staphylococcus aureus.
a
Anti-pseudomonal agents included cefepime, piperacillin/tazobactam, and carbapenem.